Mangoceuticals, Inc. (NASDAQ: MGRX) announced on February 12, 2025, that it is advancing its research into respiratory illness prevention technologies. The company is specifically focusing on finding a practical, everyday solution to combat avian influenza viruses (H5N1) within the poultry industry.
This new research initiative aims to develop a non-invasive, non-pharmaceutical water-based solution. The company has engaged Vipragen Biosciences to conduct this study, emphasizing a novel approach to disease prevention.
The focus on avian flu in poultry addresses a significant challenge for the agricultural sector and global health. A successful non-pharmaceutical solution could offer substantial benefits in disease control and food safety.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.